Microbiome modulation after severe acute kidney injury accelerates functional recovery and decreases kidney fibrosis
Kidney International · 2023-09 · 104 (3) · 470-491
DOI: 10.1016/j.kint.2023.03.024 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kidney International, 2023-09. Verfasst von Sepideh Gharaie und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Johns Hopkins University, School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Acute Kidney Injury, Reperfusion Injury, Microbiota. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: NIDDK NIH HHS.
Abstract (Originalsprache)
Targeting gut microbiota has shown promise to prevent experimental acute kidney injury (AKI). However, this has not been studied in relation to accelerating recovery and preventing fibrosis. Here, we found that modifying gut microbiota with an antibiotic administered after severe ischemic kidney injury in mice, particularly with amoxicillin, accelerated recovery. These indices of recovery included increased glomerular filtration rate, diminution of kidney fibrosis, and reduction of kidney profibrotic gene expression. Amoxicillin was found to increase stool Alistipes, Odoribacter and Stomatobaculum species while significantly depleting Holdemanella and Anaeroplasma. Specifically, amoxicillin treatment reduced kidney CD4+T cells, interleukin (IL)-17 +CD4+T cells, and tumor necrosis factor-α double negative T cells while it increased CD8+T cells and PD1+CD8+T cells. Amoxicillin also increased gut lamina propria CD4+T cells while decreasing CD8+T and IL-17+CD4+T cells. Amoxicillin did not accelerate repair in germ-free or CD8-deficient mice, demonstrating microbiome and CD8+T lymphocytes dependence for amoxicillin protective effects. However, amoxicillin remained effective in CD4-deficient mice. Fecal microbiota transplantation from amoxicillin-treated to germ-free mice reduced kidney fibrosis and increased Foxp3+CD8+T cells. Amoxicillin pre-treatment protected mice against kidney bilateral ischemia reperfusion injury but not cisplatin-induced AKI. Thus, modification of gut bacteria with amoxicillin after severe ischemic AKI is a promising novel therapeutic approach to accelerate recovery of kidney function and mitigate the progression of AKI to chronic kidney disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Johns Hopkins University, School of Medicine, Baltimore, Maryland, USA.
- Department of Physiology, Johns Hopkins University, School of Medicine, Baltimore, Maryland, USA.
- Department of Pathology, Johns Hopkins University, School of Medicine, Baltimore, Maryland, USA.
- Department of Medicine, George Washington University, School of Medicine and Health Sciences, Washington, District of Columbia, USA.
- Department of Medicine, Johns Hopkins University, School of Medicine, Baltimore, Maryland, USA. Electronic address: hrabb1@jhmi.edu.
Förderung
- NIDDK NIH HHS
Zitieren
APA
Gharaie, S., Lee, K., Newman-Rivera, A. M., Xu, J., Patel, S. K., Gooya, M., Arend, L. J., Raj, D. S., Pluznick, J., Parikh, C., Noel, S., & Rabb, H. (2023). Microbiome modulation after severe acute kidney injury accelerates functional recovery and decreases kidney fibrosis. Kidney International, 104(3), 470-491. https://doi.org/10.1016/j.kint.2023.03.024
Vancouver
Gharaie S, Lee K, Newman-Rivera AM, Xu J, Patel SK, Gooya M, et al. Microbiome modulation after severe acute kidney injury accelerates functional recovery and decreases kidney fibrosis. Kidney International. 2023;104(3):470-491. doi:10.1016/j.kint.2023.03.024
BibTeX
@article{Gharaie2023,
author = {Gharaie, Sepideh and Lee, Kyungho and Newman-Rivera, Andrea M and Xu, Jiaojiao and Patel, Shishir Kumar and Gooya, Mahta and Arend, Lois J and Raj, Dominic S and Pluznick, Jennifer and Parikh, Chirag and Noel, Sanjeev and Rabb, Hamid},
title = {Microbiome modulation after severe acute kidney injury accelerates functional recovery and decreases kidney fibrosis},
journal = {Kidney International},
year = {2023},
volume = {104},
number = {3},
pages = {470--491},
doi = {10.1016/j.kint.2023.03.024}
}
EUVIMED